Benefit-risk assessment conceptual framework for exposure to biologics during pregnancy

被引：0
|
作者：
Bozzi, Laura [1 ]
Jacobson, Melanie H. [2 ]
Yost, Emily [3 ]
Cafone, Joseph [1 ]
Sheahan, Anna [4 ]
Levitan, Bennett S. [1 ]
Nelson, Robert M. [5 ]
机构：
[1] Janssen Pharmaceut, Beerse, Belgium
[2] Janssen Res & Dev, Raritan, NJ USA
[3] Janssen, Beerse, Belgium
[4] Janssen Res & Dev LLC, Raritan, NJ USA
[5] Johnson & Johnson, New Brunswick, NJ USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1124
引用
收藏
页码：529 / 529
页数：1
相关论文
共 50 条
  • [1] A Benefit-Risk Conceptual Framework for Biologic Use During Pregnancy: A Mini-Review
    Bozzi, Laura M.
    Jacobson, Melanie H.
    Yost, Emily
    Sheahan, Anna
    Cafone, Joseph
    Komatsu, Yosuke
    Schwartz, Lisa
    Levitan, Bennett
    Nelson, Robert M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (06) : 1251 - 1257
  • [2] FDA's Benefit-Risk Framework for Human Drugs and Biologics: Role in Benefit-Risk Assessment and Analysis of Use for Drug Approvals
    Lackey, Leila
    Thompson, Graham
    Eggers, Sara
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (01) : 170 - 179
  • [3] A Unified Framework for Classification of Methods for Benefit-Risk Assessment
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Choudhry, Niteesh
    Bykov, Katsiaryna
    Kohler, Kristijan H.
    Martin, Diane P.
    Gagne, Joshua J.
    VALUE IN HEALTH, 2015, 18 (02) : 250 - 259
  • [4] A UNIFIED FRAMEWORK FOR CLASSIFICATION OF METHODS FOR BENEFIT-RISK ASSESSMENT
    Najafzadeh, M.
    Schneeweiss, S.
    Choudhry, N. K.
    Bykov, K.
    Kahler, K.
    Martin, D.
    Arcona, S.
    Rogers, J. R.
    Gagne, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A3 - A3
  • [5] A Unified Framework for Classification of Methods for Benefit-Risk Assessment
    Najafzadeh, Mehdi
    Schneeweiss, Sebastian
    Choudhry, Niteesh K.
    Bykov, Kate
    Kahler, Kristijan
    Martin, Diane P.
    Arcona, Stephen
    Gagne, Joshua J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 240 - 241
  • [6] Antidepressant use during pregnancy: the benefit-risk ratio
    Koren, Gideon
    Nordeng, Hedvig
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (03) : 157 - 163
  • [7] Refining the Benefit-Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters
    Walker, S.
    Liberti, L.
    McAuslane, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 179 - 182
  • [8] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
    Warner, Margaret R.
    Wolka, Anne M.
    Noel, Rebecca A.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2016, 50 (03) : 342 - 346
  • [9] Implementing Benefit-Risk Assessment for the Periodic Benefit-Risk Evaluation Report
    Margaret R. Warner
    Anne M. Wolka
    Rebecca A. Noel
    Therapeutic Innovation & Regulatory Science, 2016, 50 : 342 - 346
  • [10] A Universal Framework for the Benefit-Risk Assessment of Medicines: Is This the Way Forward?
    Stuart Walker
    Neil McAuslane
    Lawrence Liberti
    James Leong
    Sam Salek
    Therapeutic Innovation & Regulatory Science, 2015, 49 : 17 - 25
12345